anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Participants will receive amivantamab low dose or high dose intravenous (IV) infusion based on body weight from Cycle 1 Day 1, Day 2, and subsequently Day 8, Day 15, and Day 22 and then every 2 weeks from Cycle 2 in combination with cetrelimab IV infusion from Cycle 1 Day 2 (after the Day 2 infusion of amivantamab). Doses will be escalated or de-escalated based on the dose limiting toxicities (DLTs) and the recommended Phase 2 combination dose (RP2CD) will be determined by the study evaluation team (SET).
PURPOSE:To obtain the titled lymphocyte (killer T-cell) reactive specifically to cancer cells, by sensitizing a lymphocyte with a cancer cell-originated saccharide-chain- relating antigen (GRA). CONSTITUTION:The cell membrane component is removed from the GRA of the cultured cancer cell, transplanted cancer cell, spontaneously occured cancer cell, chemically or virally induced cancer cell, etc. of man or animals, and the GRA is treated with lectin (e.g. peanut lectin, castor bean lectin, etc.) which bonds specifically to the terminal galactose. The GRA bonded with the lectin is separated therefrom, and the killer T-cell can be obtained by culturing lymphocyte in a medium containing said GRA at about 7.2 pH and 37 deg.C. The killer T-cell can be proliferated indefinitely in the above medium containing a T-cell prolifration factor, keeping the activity of the cell, and can be stored in liquefied nitrogen stably for a long perid. Representative examples of the lymphocyte are GRA-1-KT and GRA-M-1-KT.
Provided herein is to a blockchain-implemented method and a system for retrieving electronic medical and health records by blockchain. The method is operated in a serving system that is used to manage one or more medical-health record databases and users' blockchain IDs. The plurality of medical-health record databases can be set by different medical-health institutions. The serving system identifies the user's blockchain ID when it receives a request from a terminal device. The user uses a query interface to generate a query command. The serving system then obtain one or more medical-health record indexes via blockchain verification according to the user's blockchain ID and the query command. The medical-health records corresponding to the indexes can therefore be obtained after querying the database.
Adults

Adult surgical patients receiving general balanced anesthesia (barbiturate: thiopental, methohexital, or thiamylal; opioid: alfentanil or fentanyl; nitrous oxide; neuromuscular blockade: succinylcholine/curare and/or vecuronium or atracurium; and supplemental isoflurane) who received no prophylactic antiemetics and who experienced nausea and/or vomiting within 2 hours postoperatively were evaluated in two double-blind US trials involving 441 patients. Patients who experienced an episode of postoperative nausea and/or vomiting were given ondansetron injection (4 mg) intravenously over 2 to 5 minutes, and this was significantly more effective than placebo. The results of these trials are summarized in Table 12. 

The populations in Table 12 consisted mainly of women undergoing laparoscopic procedures. 

Repeat Dosing in Adults: In patients who do not achieve adequate control of postoperative nausea and vomiting following a single, prophylactic, preinduction, intravenous dose of ondansetron 4 mg, administration of a second intravenous dose of ondansetron 4 mg postoperatively does not provide additional control of nausea and vomiting. 

Pediatrics

One double-blind, placebo-controlled, US trial was performed in 351 male and female outpatients (aged 2 to 12 years) who received general anesthesia with nitrous oxide and no prophylactic antiemetics. Surgical procedures were unrestricted. Patients who experienced two or more emetic episodes within 2 hours following discontinuation of nitrous oxide were randomized to either single intravenous doses of ondansetron (0.1 mg/kg for pediatric patients weighing 40 kg or less, 4 mg for pediatric patients weighing more than 40 kg) or placebo administered over at least 30 seconds. Ondansetron was significantly more effective than placebo in preventing further episodes of nausea and vomiting. The results of the trial are summarized in Table 13.
Muscle Energy Technique is given in the form of post isometric relaxation with 5-7 sec hold for 8-10 repetitions followed by a gentle passive stretch. Only 20% resistance is offered to the isometric contraction.
Inflammatory monocytes (iMO) are recruited from the bone marrow to the brain during viral encephalitis. C-C motif chemokine receptor (CCR) 2 deficiency substantially reduces iMO recruitment for most, but not all encephalitic viruses. Here we show CCR7 acts synergistically with CCR2 to control this process. Following Herpes simplex virus type-1 (HSV-1), or La Crosse virus (LACV) infection, we find iMO proportions are reduced by approximately half in either Ccr2 or Ccr7 knockout mice compared to control mice. However, Ccr2/Ccr7 double knockouts eliminate iMO recruitment following infection with either virus, indicating these receptors together control iMO recruitment. We also find that LACV induces a more robust iMO recruitment than HSV-1. However, unlike iMOs in HSV-1 infection, LACV-recruited iMOs do not influence neurological disease development. LACV-induced iMOs have higher expression of proinflammatory and proapoptotic but reduced mitotic, phagocytic and phagolysosomal transcripts compared to HSV-1-induced iMOs. Thus, virus-specific activation of iMOs affects their recruitment, activation, and function.
The present invention provides a new strain of turkey tail mushroom ( Trametes versicolor  (L.: Fr.) Pilat) having excellent biological activities (Accession number: FERM BP-10633). The strain is excellent in platelet aggregation inhibitory effect, chemokine gene expression inhibitory effect, antimutagenic effect, antitumor effect, antihypertensive effect, and immunomodulatory effect. The effect of the strain is enhanced synergistically by combining with microalgae and other basidiomycetes. The turkey tail mushroom of the present invention has high safety, and a possibility that a side effect is caused because of long-term continuous use is very low. Thus, it is useful for food/drink, cosmetics, pharmaceuticals or the like, the objective of which is the prevention and improvement in inflammation, allergy, tumor, and other diseases. The turkey tail mushroom strain of the present invention has very high hyphal growth property and very high physiological functions compared with conventional strains; therefore, it can be used stably.
Conventional hemodialysis uses large amounts of water, which hinders travel possibilies for home hemodialysis (HD) patients. We have developed a recycling system using 25-30 l dialysate per dialysis. In vitro investigations show that this results in adequate dialysis.

12 HD patients will be studied during two dialysis sessions. The first HD will be a conventional 4 hour dialysis, using single pass dialysate. The second will be an 8-hour HD using multipass (recycled) dialysate 25-30 l. Clearance of urea, creatinine, phosphate and cobalamin will be measured both in the patient and the dialysate. Patient symptoms will be recorded.
Control group consisting of general healthy eating advice through daily text messages for 2 months (delivery phase). A reinforcement phase of 2-months will follow to repeat the text messages.
* TAMIFLU is not a substitute for early influenza vaccination on an annual basis as recommended by the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices.
  * Influenza viruses change over time. Emergence of resistance substitutions could decrease drug effectiveness. Other factors (for example, changes in viral virulence) might also diminish clinical benefit of antiviral drugs. Prescribers should consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use TAMIFLU [see Microbiology (12.4)].
  * TAMIFLU is not recommended for patients with end-stage renal disease not undergoing dialysis [see Dosage and Administration (2.4) and Use in Specific Populations (8.6)].
PURPOSE: To obtain a new compound, having excellent inhibiting actions with high enzymic selectivity on aldose reductases participating in the production of sorbitol and useful as a preventing and therapeutic agent for diabetic complications. CONSTITUTION: A compound of the formula [two of Ra to Rc are 0 and the remaining one is S, a lower alkylene, etc.; X is benzyl, benzothiazolylmethyl, etc.; R is H or a lower alkyl; (n) is 1-3; Z is a direct bond (in this case, the heterocyclic ring is a 5-membered one) or a bond through one C atom (in this case, the heterocyclic ring is a 6-membered one)], e.g. 3-(3-nitrobenzyl)-5- methylidene-2,4-dioxoimidazolidine-1-acetic acid. This compound is obtained by reacting, e.g. an oxamic acid having a group corresponding to the substituent group X with glycine esterified with trimethylsilylethyl, etc., then refluxing the resultant product with sodium acetate in acetic anhydride and subsequently hydrolyzing the prepared product.
A daily gonadotropin dose (typically 75-450 IU) will be assigned and adjusted, based on clinical criteria and, if known, past response to hormones. Recombinant human FSH (rhFSH) will be given as a daily subcutaneous injection, as is performed, by patients at home, in routine clinical practice.
NEW MATERIAL:The alkylenedioxybenzene derivative of formulaI(X is group of formula II or formula III; m is 1-3) and its acid addition salt. EXAMPLE:5-[2-[(1,4-Benzodioxan-2-ylmethyl)amino]acetyl]-1,3-benzpdioxole. USE:Useful as a hypotensor. It has rapid and long-acting drug action, low acute toxicity, and high safety. PROCESS:The compound of formulaIwherein X is group of formula II can be prepared, e.g. by reacting the halogenoacetylalkylenedioxybenzene derivative of formula IV (Y is halogen) with the amine of formula V preferably in a solvent such as water, dioxane, etc. usually at -10-+150 deg.C, preferably between 0 deg.C and room temperature. The obtained compound can be converted to another compound of formulaIwherein X is group of formula III by treating with a metal hydride salt in a solvent.
This study is a two-group, pre- and post-test, parallel, non-blind randomized controlled trial to test the effectiveness of the "chin retraction resistance exercise program". The convenient sampling will be used to select inpatients with stroke and dysphagia in a regional hospital from southern Taiwan. In this study, the investigators will use block randomization to assign participants to either experimental or control group, and use sealed opaque envelopes to conceal the allocation sequences. The target sample size of 80 participants will be enrolled according to sample size calculation. The CTAR exercise is to tighten a rubber ball which placed between the chin and the sternum, and to perform 3 cycles of isometric exercise and isotonic exercise. The CTAR protocol is perform CTAR exercises three times a day, five days a week, and for four weeks. The research nurses will assist in screen and recruit subjects in clinical ward units, perform the CTAR exercise protocol, and collect dates. The independent t-test will be used to compare the change effect of the two groups.
BACKGROUND: Subclinical hypothyroidism (SCH) is characterized by elevated levels of thyroid hormone (TSH) and normal levels of free thyroxine (FT4). The outcomes of SCH patients are crucial for determining treatment plans; therefore, our aim is to summarize the existing prospective studies to understand the changes in thyroid function over time in SCH patients and the factors influencing these changes, providing references for clinical diagnosis and treatment.
METHODS: We searched PubMed, Embase, Cochrane Library, and Web of Science for prospective follow-up studies on natural outcomes of SCH published until September 2024. Results are presented as the overall risk ratio (RR) and 95% confidence intervals (CI).
RESULTS: We reviewed 8 prospective follow-up studies involving 1,859 individuals and extracted data from them for a meta-analysis. We found that when TSH levels are ≥ 10 mU/L, patients with SCH are more likely to progress to overt hypothyroidism (OH) (RR11.38, 95%CI 4.98-26.03, P<0.001) and were less likely to return to normal TSH levels (RR 0.20, 95%CI 0.09-0.42, P<0.001) compared to patients with TSH between 4.5 and 9.9 mU/L. In addition, patients who test positive for thyroid peroxidase antibodies (TPOAb) are more likely to progress to OH (RR 2.53, 95% CI 1.86-3.44, P < 0.001) and less likely to return to euthyroidism (RR 0.68, 95% CI 0.60-0.76, P < 0.001) compared to TPOAb-negative patients.
CONCLUSION: The results indicated that a large proportion of patients diagnosed with SCH will return to normal TSH levels or maintain SCH. Additionally, patients with TSH levels ≥ 10 mU/L or positive for TPOAb are more likely to experience progression and should be closely monitored. However, we did not find any gender differences in the natural outcome of SCH.
An abuse-deterrent pharmaceutical composition has been developed to reduce the likelihood of improper administration of drugs, especially drugs such as opiods. In the preferred embodiment, the drug is modified to increase its lipophilicity by forming a salt between the drug and one or more fatty acids wherein the concentration of the one or more fatty acids is one to 15 times the molar amount of the active agent, preferably two to ten times the molar amount of the active agent. In one embodiment the modified drug is homogeneously dispersed within microparticles composed of a material that is either slowly soluble or not soluble in water. In some embodiments the drug containing microparticles or drug particles are coated with one or more coating layers, where at least one coating is water insoluble and preferably organic solvent insoluble. The abuse-deterrent composition prevents the immediate release of a substantial portion of drug, even if the physical integrity of the formulation is compromised (for example, by chopping with a blade or crushing) and the resulting material is placed in water, snorted, or swallowed. However, when administered as directed, the drug is slowly released from the composition as the composition is broken down or dissolved gradually within the GI tract by a combination of enzymatic degradation, surfactant action of bile acids, and mechanical erosion.
The invention discloses terbinafine hydrochloride tablets, a preparation method thereof, and an impurity and quality detection method. The terbinafine hydrochloride tablet consists of terbinafine hydrochloride and pharmaceutic adjuvants, wherein the pharmaceutic adjuvants comprise a filling agent, a disintegrating agent, an adhesive, a lubricant and a glidant; wherein: the filler is microcrystalline cellulose; the disintegrating agent is sodium carboxymethyl starch; the adhesive is hydroxypropyl methylcellulose E50; the lubricant is magnesium stearate; the glidant is silicon dioxide. The invention adopts hydroxypropyl methylcellulose E50 as an adhesive and carries out wet granulation. Can enhance granule viscosity, improve dissolution rate and release rate of tablet, improve compressibility, and stabilize product quality. Furthermore, the invention also provides an impurity and quality detection method of the terbinafine hydrochloride tablet. The impurity and quality detection method can detect 6 impurity peaks, each impurity is well separated from a main peak, and the method has the characteristics of good specificity, high reproducibility and accurate measurement result.
Insulin crystals produced entirely or partly from bovine pancreas glands are heated, while maintaining their water content above 8%, e.g. as undried crystals or in aqueous suspension with appropriate buffer, at a temperature above 20 DEG  C., and for such a period of time that a suspension thereof shows on injection an insulin action that is protracted compared with that of the untreated crystals.  The crystals may be so heat-treated while in suspension in a sterile aqueous medium of pH below 7.  The process is applicable to insulin crystals having a high metal content. Examples are given in which a buffered suspension of insulin crystals from ox pancreas glands is treated (1) at 45 DEG  C. for 2 weeks, (3) at 45 DEG  C. for 4 weeks, (5) at 70 DEG  C. for 7 hours. Specification 733,740 is referred to.
<P>PROBLEM TO BE SOLVED: To obtain a cosmetic suitable for making pore existence optically inconspicuous without a specific make technique.  <P>SOLUTION: The cosmetic in an emulsion dosage form comprises 0.005-10 mass% of spherical powder having 3-20 μm particle diameter. The spherical powder is preferably a silicic anhydride which may contain a 1-4C alkyl group or phenyl group as a substituent group replacing oxygen in a silicon-oxygen bond. A silicic anhydride having no porous layer at least on the surface and/or a methylpolysiloxane resin or a methylphenylsiloxane resin which may have a crosslinking structure is preferable as the spherical powder. The cosmetic is preferably used in a way in which a foundation is applied to the top of the coated part of the cosmetic.  <P>COPYRIGHT: (C)2007,JPO&INPIT
BACKGROUND: It is thought that 50% of healthcare providers experience Second Victim Syndrome (SVS) in the course of their practice. The manifestations of SVS varies between individuals, with potential long-lasting emotional effects that impact both the personal lives and professional clinical practice of affected persons. Although surgeons are known to face challenging and high-stress situations in their profession, which can increase their vulnerability to SVS, majority of studies and reviews have focused squarely on nonsurgical physicians.
METHODS: This scoping review aimed to consolidate existing studies pertaining to a surgeon's experience with SVS, by broadly examining the prevalence and impact, identifying the types of responses, and evaluating factors that could influence these responses. The scoping review protocol was guided by the framework outlined by Arksey and O'Malley and ensuing recommendations made by Levac and colleagues. Three databases (MEDLINE, EMBASE and Cochrane Library) were searched from inception till March 19, 2023.
RESULTS: A total of 13 articles were eligible for thematic analysis based on pre-defined inclusion criteria. Effects of SVS were categorized into Psychological, Physical and Professional impacts, of which Psychological and Professional impacts were particularly significant. Factors affecting the response were categorized into complication type, surgeon factors and support systems.
CONCLUSION: SVS adds immense psychological, emotional and physical burden to the individual surgeon. There are key personal, interpersonal and environmental factors that can mitigate or exacerbate the effects of SVS, and greater emphasis needs to be placed on improving availability and access to services to help surgeons at risk of SVS.
Adult Patients

Bradycardia, sinus arrest, and heart block have occurred with ivabradine tablets. The rate of bradycardia was 6.0% per patient-year in patients treated with ivabradine tablets (2.7% symptomatic; 3.4% asymptomatic) and 1.3% per patient-year in patients treated with placebo. Risk factors for bradycardia include sinus node dysfunction, conduction defects (e.g., 1 stor 2 nddegree atrioventricular block, bundle branch block), ventricular dyssynchrony, and use of other negative chronotropes (e.g., digoxin, diltiazem, verapamil, amiodarone). Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients with risk factors such as use of QTc prolonging drugs [see Adverse Reactions (6.2)] . 

Concurrent use of verapamil or diltiazem will increase ivabradine tablets exposure, may themselves contribute to heart rate lowering, and should be avoided [see Clinical Pharmacology (12.3)] . Avoid use of ivabradine tablets in patients with 2 nddegree atrioventricular block unless a functioning demand pacemaker is present [see Contraindications (4)].
The aims of this study are to retrospectively evaluate the diagnostic value of T1- and T2-weighted 3-T magnetic resonance imaging (MRI) for postmortem detection of myocardial infarction (MI) in terms of sensitivity and specificity and to compare the MRI appearance of the infarct area with age stages. Postmortem MRI examinations (n = 88) were retrospectively reviewed for the presence or absence of MI by two raters blinded to the autopsy results. The sensitivity and specificity were calculated using the autopsy results as the gold standard. A third rater, who was not blinded to the autopsy findings, reviewed all cases in which MI was detected at autopsy for MRI appearance (hypointensity, isointensity, hyperintensity) of the infarct area and the surrounding zone. Age stages (peracute, acute, subacute, chronic) were assigned based on the literature and compared with the age stages reported in the autopsy reports. The interrater reliability between the two raters was substantial (κ = 0.78). Sensitivity was 52.94% (both raters). Specificity was 85.19% and 92.59%. In 34 decedents, autopsy identified an MI (peracute: n = 7, acute: n = 25, chronic: n = 2). Of 25 MI classified as acute at autopsy, MRI classified peracute in four cases and subacute in nine cases. In two cases, MRI suggested peracute MI, which was not detected at autopsy. MRI could help to classify the age stage and may indicate the area for sampling for further microscopic examination. However, the low sensitivity requires further additional MRI techniques to increase the diagnostic value.
Study population was consisted by healthy volunteers from hospital staff of physical therapy department, Intensive Care Unit, and cleaning service. All subjects were men and women aged between 20 and 65 years old, who never had major problems with the respiratory system or with the hand flexors.
The present invention mask helps contain the spread of viruses, bacteria, and other microbes that spread through human repertory ingestion while allowing users to utilize a cellular communication device in a private manner. The present invention employs an impervious privacy mask with an elongated mouth-piece having a semi-circular opening for a user's mouth and a second opening coupled with a transfer tube in which a user's voice travels until it reaches the receiver of a cellular communication device, cellular phone, intelligent personal assistant, or computer, inserted in a head-set equipped with ear-pieces. The present invention is a device allowing both speaking and listening with privacy since it prevents both the user's voice to spread in the surrounding environment and outside noises to disturb the communication. Additionally, it prevents microbes contained within the user's emitted breath when speaking to be spread to the outside environment and to contaminate ambient air. The mask also functions as a device to utilize a cellular phone while utilizing a separate, protective facemask thus protecting the user from inhaling viruses, bacteria and other microbes. It can also be combined with a surgical mask to provide protection against contamination coming from outside. Such a device can be decontaminated after each use with proper chemicals.